Monitor for potential downward pressure on the stock price due to the dilutive offering and recent insider selling, despite positive clinical data for MZE829; watch for updates on the pivotal development program timeline.
Price Chart
Executive Summary
Maze Therapeutics is raising $145.7 million through a public offering of 5.54 million shares and 850,000 pre-funded warrants at $23.50 per share, with proceeds intended for advancing its MZE829 and MZE782 clinical programs. The offering follows positive Phase 2 data for MZE829 in kidney disease and comes amid recent insider selling.
Key Facts
- Offering 5,540,000 shares and 850,000 pre-funded warrants at $23.50 per share
- Estimated net proceeds of $144.7 million after expenses
- Proceeds to be used primarily for advancing MZE829 and MZE782 clinical programs
- Recent positive Phase 2 data for MZE829 showed 35.6% mean reduction in uACR
- Recent insider activity: 3 sells totaling $593K in the last 30 days
Financial Impact
Raises $145.7 million in gross proceeds, increasing share count by 11.3% and diluting existing shareholders
Risk Factors
- Immediate dilution of $14.40 per share for new investors
- Potential for share price decline due to increased supply and recent insider selling
- No guarantee that the capital raised will lead to successful regulatory approval or commercialization
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 424B5 Filing (Primary) | 0001193125-26-170687 |
| Document: d15217dexfilingfees.htm | 0001193125-26-170687 |
| Document: 0001193125-26-170687-index-headers.html | 0001193125-26-170687 |
| Document: 0001193125-26-170687-index.html | 0001193125-26-170687 |
| Document: 0001193125-26-170687.txt | 0001193125-26-170687 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 4, 2026 27d ago | Insider Cluster | $26.37 $24.23 | ▼ −8.12% | ▼ −7.00% | $26.69 (+1.20%) |
Sep 4, 2026 27d ago | Insider Cluster | $26.37 $24.23 | ▼ −8.12% | ▼ −7.00% | $26.69 (+1.20%) |
Sep 3, 2026 29d ago | Insider Cluster | $25.87 $24.60 | ▼ −4.91% | ▼ −3.76% | $26.69 (+3.16%) |
Sep 2, 2026 29d ago | 144 | $25.87 $24.60 | ▼ −4.91% | ▼ −3.76% | $26.69 (+3.16%) |
Sep 1, 2026 4w ago | 144 | $26.72 $24.82 | ▼ −7.11% | ▼ −6.15% | $26.69 (−0.12%) |
Aug 17, 2026 6w ago | 3 | $29.13 $30.42 | ▲ +4.43% | ▲ +4.63% | $26.69 (−8.38%) |
Aug 11, 2026 7w ago | Press Release | $27.53 $29.75 | ▲ +8.06% | ▲ +8.51% | $26.69 (−3.06%) |
Aug 7, 2026 8w ago | Institutional Cluster | $28.65 $27.18 | ▼ −5.13% | ▼ −5.53% | $26.69 (−6.85%) |
Aug 5, 2026 8w ago | Insider Cluster | $27.81 $27.53 | ▼ −1.01% | ▼ −1.36% | $26.69 (−4.04%) |
Jul 2, 2026 13w ago | Insider Cluster | $31.26 $32.42 | ▲ +3.71% | ▲ +2.78% | $26.69 (−14.63%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access